|Publishing Date :||April, 2015|
|Report Code :||HCID100|
Single license $4,500
Site license $6,300
Global license $7,200
“Influenza Pipeline Analysis” report gives comprehensive insight on various drugs being developed for the treatment of influenza. The report discusses the unmet needs and strategies to overcome those. Also, covers some of the hot targets in research for treatment.
This report enables Pharmaceutical /Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative opportunities in the influenza market. The report also provides strategic insights on medicines that are likely to have an impact on influenza treatment space and potentially alter standards of care in the foreseeable future. This helps in identifying the Best-in-class & First-in-class drugs.
Some of the key sections of report are given below:
In this section, influenza epidemiology is covered to understand the potential significance and impact of the disease.
- Global prevalence & incidence rate based-on age groups and gender
In this section, global drugs market would be covered region-wise along with the CAGRs.
- Forecasting model for market
- Market dynamics
- Global and regional drugs market
Pipeline analysis sections provides deeper insights on various drugs in discovery & development, pipelines from major companies would be covered along with potential targets, mechanism of action, current development status.
- Pipeline analysis by developmental stage
- Pipeline analysis by leading players
- Pipeline analysis by targets & mechanism of action
- IP status
Key Players Analysis
The key player’s analysis section provides an in-depth understanding of various companies working on influenza in focus and their pipelines with development phase as well as understanding partnering strategies such as deals entered by the company.
- Global key players overview
- Global key players pipeline data
- Global key players deal (collaborations, licensing, service agreements, grants, funds etc.)